Scancell Holdings (GB:SCLP) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Scancell Holdings has announced that Genmab has exercised its option for a second commercial license agreement, granting Genmab exclusive rights to develop and commercialize a monoclonal antibody from Scancell’s GlyMab® platform. This move could potentially yield Scancell up to $630 million in milestone payments and royalties from net sales. This strategic partnership highlights Scancell’s innovative approach in developing therapeutics targeting cancer-specific glycans.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
